This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025. Editor's Footnote In May 2025, Secretary Robert F. Kennedy Jr.
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease. Kobayashi M, Leidner AJ, Gierke R, et al. MMWR Morb Wkly Rep. 2025;74:1-8. doi:10.15585/mmwr.mm7401a1 3.
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
Reduced immunity from COVID-19 precautions and low vaccination rates, especially among children and vulnerable groups, worsened the influenza season's impact. H3N2 is especially worrisome because of its frequent mutations, which can hinder immune recognition and response. 4 Immune response data showed that just 50.9%
Klein, MD, FRCP (C), FACC, FAHA, FASE, FESC, director at Pericardial Disease Center and professor of medicine, and Sean Krohn, PharmD, CSP, MSCS, lead clinical pharmacist, specialtypharmacy, discussed a complex case of severe pericarditis in an elderly patient who could not tolerate traditional treatments like NSAIDs or colchicine.
4 Novak added that these services align well with appointment-based models and can be layered with immunizations, chronic disease monitoring, and medication therapy management. Addressing Barriers and Finding Solutions Despite the promise of these services, challenges remain.
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Addressing pharmacy deserts and enhancing interdisciplinary collaboration, especially with social workers, are crucial for improving health care access.
The study aimed to evaluate both safety and preliminary efficacy outcomes, with a specific focus on hematologic toxicity, pharmacokinetics, and immune system effects. Flow cytometry data indicated no significant increases in immune checkpoint markers typically associated with T-cell exhaustion.
During the session “Collaborative Practice, Statewide Protocols, and Independent Prescriptive Authority: How Pharmacy is Expanding Services to Increase Access to Patients,” Klepser highlighted the importance of moving beyond product dispensing to provide higher-level services, such as immunizations and medication therapy management.
link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
Receiving CAR T therapy can take several weeks, and though very effective against difficult-to-treat cancers, it can sometimes cause life-threatening adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
This single-center, retrospective, observational study included data from electronic health records and specialtypharmacies from January 1, 2023, to June 1, 2024, with specialtypharmacy dispensing data specifically used to identify patients who had received Humira and a biosimilar during the study period.
Pharmacy Times : As immunotherapies expand into the solid tumor space, clinicians are reporting cases of ICANS and CRS. Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? All patients should have immunotherapy first. It was approved last year.
Because biologics and biosimilar products are large and complex proteins, there is a higher risk of a patient’s body identifying them as an “outside source” and mounting an immune response to them. Our bodies don't like foreign sources. They like the things that it creates itself.
Immune effector cell–associated neurotoxicity syndrome was less common but observed in 28% (grade ≥3, 5%). 2025029274 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Doi:10.1182/blood.2025029274 Subscribe Now!
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content